Screening small molecule drugs using neural cells differentiated from human embryonic stem cells
First Claim
1. A method of screening a compound for its effect on neural cells or a neural cell activity, comprising:
- a) obtaining from an established line of primate pluripotent stem (pPS) cells a population of cells in which at least ˜
60% of cells in the population express A2B5, NCAM, MAP-2, or Nestin;
b) combining the cell population with the compound;
c) determining any change to phenotype or activity of cells in the population that results from being combined with the compound; and
d) correlating the change with an effect of the compound on neural cells or a neural cell activity.
2 Assignments
0 Petitions
Accused Products
Abstract
This invention provides populations of neural progenitor cells and differentiated neurons, obtained by culturing pluripotent cells in special growth cocktails. The technology can be used to produce progenitors that proliferate through at least ˜40 doublings, while maintaining the ability to differentiate into a variety of different neural phenotypes, including dopaminergic neurons. The neural progenitors and terminally differentiated neurons of this invention can be generated in large quantities for use in drug screening and the treatment of neurological disorders.
-
Citations
22 Claims
-
1. A method of screening a compound for its effect on neural cells or a neural cell activity, comprising:
-
a) obtaining from an established line of primate pluripotent stem (pPS) cells a population of cells in which at least ˜
60% of cells in the population express A2B5, NCAM, MAP-2, or Nestin;
b) combining the cell population with the compound;
c) determining any change to phenotype or activity of cells in the population that results from being combined with the compound; and
d) correlating the change with an effect of the compound on neural cells or a neural cell activity. - View Dependent Claims (3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)
-
-
2. A method of screening a compound for its effect on neural cells or a neural cell activity, comprising:
-
a) combining the compound with a cell population characterized in that at least ˜
60% of cells in the population have the same genome as an established line of human embryonic stem (hES) cells and express A2B5, NCAM, MAP-2, or Nestin;
b) determining any change to phenotype or activity of cells in the population that results from being combined with the compound; and
c) correlating the change with an effect of the compound on neural cells or a neural cell activity.
-
Specification